Home › Medicare Part D GLP-1 cost guide

Last reviewed Nov 6, 2026

How much does Medicare Part D cost for GLP-1 weight-loss pills?

We may earn a commission from some links on this page. How we make money.

Short answer: Through the Medicare GLP-1 Bridge, most Medicare enrollees pay $50 per month for Wegovy (pill or injection), Zepbound KwikPen, or Foundayo prescribed for weight loss. That rate is fixed — it doesn't get lower with Extra Help (LIS), and it doesn't count toward your Part D deductible or out-of-pocket cap. The program runs July 1, 2026 – December 31, 2027.

2026 Medicare Part D cost structure at a glance

Cost tierStandard Part D (covered drugs)Bridge GLP-1s for weight loss
Annual deductibleUp to $615 (you pay first)$0 — Bridge claims skip the deductible
Initial coverage phaseVaries by plan (copay or coinsurance)Flat $50/month — no plan variation
Out-of-pocket cap$2,100 (covered drugs only)$50 does not count toward the $2,100 cap
Extra Help (LIS)Reduces your copays and deductibleNo effect — $50 is fixed regardless
Manufacturer savings cardsCannot be used with MedicareCannot be used — same rule applies
Medicare Prescription Payment PlanCan spread costs across the yearBridge claims are excluded

Source: CMS GLP-1 Bridge program FAQs; KFF analysis; The RX Index.

Which drugs does the Bridge cover?

The Bridge covers three FDA-approved GLP-1 medications prescribed specifically to reduce or maintain body weight:

  • Wegovy (semaglutide) pill — once-daily oral tablet, any dose (1.5–25 mg)
  • Wegovy (semaglutide) injection — weekly subcutaneous pen
  • Zepbound (tirzepatide) KwikPen — weekly auto-injector only (single-use pens and vials are excluded)
  • Foundayo (orforglipron) — once-daily oral tablet from Eli Lilly

GLP-1s prescribed for type 2 diabetes, cardiovascular risk, obstructive sleep apnea, or other Medicare-covered conditions continue through your regular Part D plan — and that spending does count toward your deductible and OOP cap.

Who qualifies?

  • Enrolled in Medicare Part D (standalone PDP or MA-PD)
  • BMI of 35 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or similar)
  • Not already getting GLP-1 coverage through your Part D plan for a different covered condition (e.g., diabetes)
  • Not enrolled in PACE or a private fee-for-service (PFFS) plan without Part D coverage

Prior authorization is required. Your prescriber submits the PA request to a single CMS-designated central processor — not your usual Part D plan. Expect an initial claim rejection at the pharmacy; the prescriber then submits PA documentation, and the medication can usually be dispensed the next business day.

What you'll actually pay in 2026 vs. 2027

PeriodMonthsYour cost (Bridge)Cash-pay alternative
July–December 20266$300 total ($50 × 6)$149–$299/month (NovoCare, LillyDirect)
Full year 202712$600 total ($50 × 12)$1,788–$3,588/year at cash-pay rates

Cash-pay prices sourced from NovoCare (Wegovy pill: $149–$299/mo) and LillyDirect (Foundayo). The $50 Bridge copay is fixed regardless of which drug, dose, or month of the year — it's the same in January and December.

Extra Help (LIS): a special note

If you receive the Low-Income Subsidy (Extra Help), you normally pay very little — sometimes $0 to $4 — for covered Part D drugs. Extra Help does not apply to Bridge GLP-1 claims. You pay $50 regardless.

For some Extra Help enrollees, $50 may actually be more than what they'd pay if the same drug were covered through their regular Part D plan for a different indication (e.g., diabetes). If you have a covered condition, ask your prescriber whether billing through your plan instead would lower your cost.

CMS and KFF have both flagged this as a potential affordability barrier for lower-income Medicare enrollees.

What happens after December 31, 2027?

The Bridge is a temporary program. CMS is running a separate, longer-term voluntary program called the BALANCE Model starting in 2027. To keep GLP-1 coverage for weight loss beyond the Bridge, your Part D plan must opt into the BALANCE Model. If your plan doesn't participate, you may need to switch plans during 2027 open enrollment (October 15 – December 7, 2027). Watch for plan communications in fall 2027.

Is there any state-by-state variation?

Not for the Bridge itself. The $50 copay and program rules are set by CMS at the federal level and apply the same way in all 50 states and U.S. territories. Medicare Advantage plans (MA-PD) may add supplemental benefits on top of the Bridge, so coverage details can vary by plan — but the $50 Bridge copay floor does not.

If you're on Medicaid (dual-eligible), the Medicare Bridge rules apply — Medicaid doesn't layer additional cost-sharing reduction onto Bridge claims.

How the Bridge compares to commercial insurance

Many commercial plans require prior authorization, a 3-month lifestyle program first, and a 5% weight-loss target to continue coverage. The Bridge skips the lifestyle requirement and doesn't have a continuation weight-loss threshold — but it does require prior authorization. See our full insurance coverage guide for employer and ACA plan details.

FAQ

What is the Medicare GLP-1 Bridge program?

Starting July 1, 2026, Medicare covers Wegovy, Zepbound KwikPen, and Foundayo for weight loss at a flat $50/month copay through December 31, 2027. Claims go through a CMS central processor, not your regular Part D plan.

Does the $50 Bridge copay count toward my Part D deductible?

No. Bridge claims are processed outside your regular Part D benefit. The $50 does not count toward the standard Part D deductible ($615 in 2026) or the $2,100 out-of-pocket cap.

Can Extra Help (LIS) lower my $50 Bridge copay?

No. Extra Help cost-sharing does not apply to Bridge GLP-1 claims. You pay $50 regardless of your income level. If you have Extra Help, compare this against what your plan would charge for the same drug under a different covered condition.

Do I need prior authorization for the Bridge?

Yes. Your prescriber submits a prior authorization request to a CMS-designated central processor — not your Part D plan. The pharmacy may see an initial rejection; medication is typically available the next business day after PA approval.

What GLP-1 drugs does the Bridge cover?

Wegovy (pill and injection), Zepbound KwikPen, and Foundayo. Zepbound single-use pens and vials are excluded. Drugs prescribed for type 2 diabetes or other covered conditions continue through your regular Part D plan.

Related guides

Sources